Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2

Xu, Lanyang; Duan, Hao; Zou, Yuheng; Wang, Jing; Liu, Huaxi; Wang, Wanyu; Zhu, Xiaoyan; Chen, Jiali; Zhu, Chengliang; Yin, Zhixin; Zhao, Xiaoshan; Wang, Qirui

doi:10.1016/j.phymed.2023.154764

Cited by 10 publications

(1 citation statement)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to causing apoptosis, XHP reduced the number of GBM 3D spheroids, the proportion of CD133-positive cells, and the expression levels of tumor stem cell markers (CD133 and SOX2) in vitro in the U87/U118 cell model. XHP downregulated tumor stem cell markers through modulation of the CD133/EGFR/Akt/mTOR pathway and inhibited tumor stem cell enrichment and self-renewal, preventing the malignant progression of glioma ( 118 ). In studies combining XHP with other antitumor agents, we found that in glioblastoma (U87 and U251), Ki67 and PCNA expression was significantly suppressed, the Bcl-2/Bax ratio was downregulated, and there was no significant in vivo toxicity of the drug in the XHP combined with motezolomide group compared with the XHP or motezolomide monoadministration group, suggesting that XHP enhances the proapoptotic effect of motezolomide by inhibiting the Akt/mTOR pathway ( 119 ).…”

Section: Chinese Patent Medicinementioning

confidence: 99%

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Ni,

Xue,

Wang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Malignant tumors are complex systemic chronic diseases and one of the major causes of human mortality. Targeted therapy, chemotherapy, immunotherapy, and radiotherapy are examples of mainstream allopathic medicine treatments that effective for intermediate and advanced malignant tumors. The ongoing use of conventional allopathic medicine has resulted in adverse responses and drug resistance, which have hampered its efficacy. As an important component of complementary and alternative medicine, Chinese medicine has been found to have antitumor effects and has played an important role in enhancing the therapeutic sensitivity of mainstream allopathic medicine, reducing the incidence of adverse events and improving immune-related functions. The combined application of adjuvant Chinese medicine and mainstream allopathic medicine has begun to gain acceptance and is gradually used in the field of antitumor therapy. Traditional natural medicines and their active ingredients, as well as Chinese patent medicines, have been proven to have excellent therapeutic efficacy and good safety in the treatment of various malignant tumors. This paper focuses on the mechanism of action and research progress of combining the above drugs with mainstream allopathic medicine to increase therapeutic sensitivity, alleviate drug resistance, reduce adverse reactions, and improve the body’s immune function. To encourage the clinical development and use of Chinese herb adjuvant therapy as well as to provide ideas and information for creating safer and more effective anticancer medication combinations, the significant functions of Chinese herb therapies as adjuvant therapies for cancer treatment are described in detail.

show abstract

Section: Chinese Patent Medicinementioning

confidence: 99%